BioScrip, Inc.

Company: BioScrip, Inc.

Deadline: TBD

Kaskela Law LLC is investigating BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS) on behalf of the Company’s shareholders.

On March 15, 2019, BioScrip announced that it had entered into an agreement to merge with Option Care Enterprises, Inc. (“Option Care”). According to the announcement, in connection with the proposed transaction BioScrip plans to issue over 542 million shares of common stock to Option Care’s shareholders, who are expected to own approximately 80% of the combined company upon completion of the transaction. Following this announcement, shares of BioScrip’s common stock declined over 20% in value.

The investigation seeks to determine whether BioScrip’s executive officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the proposed transaction, and whether BioScrip shareholders are receiving all material information in connection with the transaction.

BioScrip shareholders are encouraged to contact Kaskela Law LLC at (888) 715 – 1740, or complete the information form on this page, to receive additional information about this investigation and their legal rights and options with respect to this transaction.

Submit Your Information

  • This field is for validation purposes and should be left unchanged.